-
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
•
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of a market approval filing for its CU-10201 (4% minocycline foam agent for external use) to the National Medical Products Administration (NMPA) in China. The drug, which targets the treatment of non-nodular moderate to severe acne…
-
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
•
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its Category 1 drug candidate, UBT251, for the treatment of overweight and obesity. UBT251: A Triple Agonist…
-
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
•
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its innovative anti-tumor drug, BT02. This monoclonal antibody (mAb) targets solid tumors with a novel mechanism, representing a significant step forward in cancer…
-
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
•
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has received tacit clinical trial approval for its KL-A167 injection and SKB264 injection. These drugs are set to be assessed as a combination treatment for unresectable locally advanced, recurrent, or metastatic HR+/HER2 breast…
-
Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
•
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report for the first half of 2023. The company recorded revenues of RMB 15.28 billion (USD 2 billion), marking a 0.5% increase year-on-year (YOY). Innovative drugs contributed significantly to the total revenues, generating RMB 3.86 billion…
-
Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership
•
Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies’ expertise on a global scale, focusing on technology and commerce. Novoprotein…
-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative FuZhi 1.0 smart nuclear medicine system at the 2023 annual meeting of the Nuclear Medicine Branch of the Chinese Medical Association. This comprehensive system, which includes modules for smart patient care, smart nuclear drug management,…
